Company will feature its CorPath System during Oct. 30 symposium titled “Optimizing PCI with Robotic Angioplasty” at TCT 2013, Oct. 27 – Nov. 1
Waltham, MA – October 23, 2013 – Corindus Vascular Robotics, the leader in precision vascular robotics, will showcase its FDA-approved CorPath System at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) 2013 annual meeting, Oct. 27–Nov. 1 in San Francisco, CA. The CorPath is the first medical device to bring robotic precision and accuracy to coronary angioplasty to help optimize clinical outcomes. Experts from renowned hospitals and healthcare organizations across the country will deliver onsite presentations and answer questions about their clinical experience with robotic-assisted angioplasty and the significant advantages in stent precision and clinical outcomes utilizing the CorPath System.
Physician presentations will be highlighted during, “Optimizing PCI with Robotic Angioplasty,” a breakfast symposium co-sponsored by Philips Healthcare on Wednesday, Oct. 30, at 7:00 a.m. PDT at Moscone North, Lower Level, Room 122 at the Moscone Center.
Moderated by J. Jeffrey Marshall, M.D., FACC, FSCAI, Northeast Georgia Heart Center, and Giora Weisz, M.D., NewYork-Presbyterian Hospital/Columbia University Medical Center, “Optimizing PCI with Robotic Angioplasty” will feature presentations on the advantages offered by robotic-assisted percutaneous coronary intervention (PCI) procedures, followed by an audience discussion and Q&A on future directions of vascular robotics.
“Robotic assistance in angioplasties has shone a light on the considerable room for improvement in invasive vascular procedures, particularly in terms of stent size selection and precision in optimal placement of stents in PCI procedures,” said Dr. Marshall. “The linkage between the use of robotics during PCIs and improvement in clinical outcomes continues to increase, and the trend stands to gain further support as the interventional cardiology field embraces a future enabling the delivery of better care.”
In addition to the breakfast symposium, Dr. Weisz will also present, “Robotic Percutaneous Cardiovascular Intervention: Current Status and Future Directions” during “25 Years of Interventional Innovation: Novel Therapies and the ’Emerging’ Device Concepts for 2013,” a scientific symposia taking place Monday, Oct. 28.
“We are committed to building clinical data and evidence for robotic angioplasty,” said David Handler, President and CEO of Corindus Vascular Robotics. “Through this symposium, we will illustrate the significant impact robotic angioplasties could have on increasing procedural precision and potentially improving clinical outcomes.”
“Optimizing PCI with Robotic Angioplasty” will feature the following speakers:
For a demonstration of robotic angioplasty with the CorPath System, register here and visit TCT booth #1117.
For more information on the symposium, “Optimizing PCI with Robotic Angioplasty,” click here. To see the complete TCT 2013 agenda, please visit http://www.tctconference.com.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements:
The page you wish to view contains content that is not available in all regions. Please select your region.
